How a 90-year-old antimalarial pill is being re-engineered to fight one of the most aggressive blood cancers - Acute Myeloid Leukemia.
A comprehensive look at the phase 1 study of voruciclib for relapsed/refractory AML and B-cell malignancies, exploring CDK9 inhibition as a strategy to overcome treatment resistance.